<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901716</url>
  </required_header>
  <id_info>
    <org_study_id>Opioid2019</org_study_id>
    <nct_id>NCT03901716</nct_id>
  </id_info>
  <brief_title>Comparison of Sufentanil, Fentanyl and Remifentanil in Combination With Midazolam During Bronchoscopy Under Conscious Sedation</brief_title>
  <official_title>Comparison of Sufentanil, Fentanyl and Remifentanil in Combination With Midazolam During Bronchoscopy Under Conscious Sedation: A Randomized Double-blind Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The best opioid for bronchoscopy is still unclear.This randomized double-blind prospective
      study was conducted on a total of 60 patients who were randomly allocated into 3 groups:
      Group S received sufentanil 0.1 mcg/kg, Group F received fentanyl 1 mcg/kg and Group R
      received remifentanil target-controlled infusion with effect-site target concentration of
      1ng/ml. Patients in all groups received midazolam to achieve moderate levels of sedation as
      assessed by the Narcotrend (NT; between B1 and C2). Adverse events, patient tolerance and
      physician satisfaction were analized.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of midazolam</measure>
    <time_frame>during the procedure</time_frame>
    <description>Dosage of midazolam applied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of cough</measure>
    <time_frame>during the procedure</time_frame>
    <description>total times of cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's subjective tolerance</measure>
    <time_frame>30minutes after bronchoscopy</time_frame>
    <description>the intensity of four key symptoms during bronchoscopy (pain, nausea, breathlessness and cough) and memory using a visual analogic scale (VAS: 1 mm: excellent tolerance, 100 mm very low tolerance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's global tolerance assessed by operator</measure>
    <time_frame>30minutes after bronchoscopy</time_frame>
    <description>the global tolerance of patient to the procedure using a visual analogic scale (VAS: 1 mm: excellent tolerance, 100 mm very low tolerance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of oxygen desaturation</measure>
    <time_frame>during the procedure</time_frame>
    <description>oxygen desaturation (SaO2 decrease&lt;90% for &gt;30 s)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Sufentanil</condition>
  <condition>Remifentanil</condition>
  <condition>Fentanyl</condition>
  <condition>Bronchoscopy</condition>
  <condition>Narcotrend</condition>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Patients in Group S received sufentanil 0.1 mcg/kg.</description>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Patients in Group F received fentanyl 1 mcg/kg.</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.</description>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA grade I-II

        Exclusion Criteria:

          1. psychological disorders

          2. SpO2&lt;90% in ambient air

          3. hypersensitivity or allergy to anaesthetic drugs or benzodiazepine

          4. severe chronic obstructive pulmonary disease (forced expiratory volume in 1 s ,50% of
             predicted value, requirement for oxygen therapy)

          5. unstable haemodynamic status

          6. habitual alcohol consumption

          7. asthmatic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyue Li, Professor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>ShiYue Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

